The Brave New World of clinical cancer research: Adaptive biomarker‐driven trials integrating clinical practice with clinical research
暂无分享,去创建一个
[1] D. Berry. Adaptive clinical trials in oncology , 2012, Nature Reviews Clinical Oncology.
[2] J. Neyman,et al. INADMISSIBILITY OF THE USUAL ESTIMATOR FOR THE MEAN OF A MULTIVARIATE NORMAL DISTRIBUTION , 2005 .
[3] H. Baker. 2013 San Antonio Breast Cancer Symposium. , 2014, The Lancet Oncology.
[4] D. Berry,et al. Abstract S5-02: Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL , 2013 .
[5] Lisa McShane,et al. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[6] D. Berry,et al. Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trials , 2013, Clinical trials.
[7] I. Torjesen. Large personalised medicine trial in lung cancer heralds new research partnership , 2014, BMJ : British Medical Journal.
[8] D. Berry,et al. Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy Trials , 2012, Clinical Cancer Research.
[9] D. Berry. Bayesian clinical trials , 2006, Nature Reviews Drug Discovery.
[10] Razelle Kurzrock,et al. Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative , 2012, Clinical Cancer Research.
[11] Edward S. Kim,et al. The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.
[12] K. Anderson,et al. The BATTLE trial: a bold step toward improving the efficiency of biomarker-based drug development. , 2011, Cancer discovery.
[13] Nola Hylton,et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] D. Berry,et al. I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.
[15] Nathalie Seigneuret,et al. The Innovative Medicines Initiative: an engine for regulatory science , 2014, Nature Reviews Drug Discovery.
[16] D. Berry,et al. Abstract CT227: Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: Efficacy results from the I-SPY 2 TRIAL , 2014 .
[17] Kristine R Broglio,et al. Detecting an overall survival benefit that is derived from progression-free survival. , 2009, Journal of the National Cancer Institute.
[18] Asher Mullard,et al. Multicompany trials adapt to disciplines beyond cancer , 2014, Nature Medicine.
[19] C. Stein,et al. Estimation with Quadratic Loss , 1992 .
[20] J. Brady,et al. The Belmont Report. Ethical principles and guidelines for the protection of human subjects of research. , 2015, The Journal of the American College of Dentists.